OBJECTIVE: To determine whether targeted pharmacological improvement of insulin sensitivity will normalize the associated elevations of thrombotic and inflammatory cardiovascular disease (CVD) biomarkers in individuals with insulin resistance. PATIENTS AND METHODS: Study 1 was a cross-sectional study of Asian Indians with and without diabetes mellitus and Northern European Americans without diabetes (n=14 each) conducted between December 11, 2003, and July 14, 2006. Study 2 was a secondary analysis of a double-blind randomized controlled study conducted between August 19, 2005, and August 24, 2010, that included 25 individuals with untreated diabetes or impaired fasting glucose who were randomized to receive placebo (n=13) or a combination of metformin, 1000 mg twice daily, and pioglitazone, 45 mg daily (n=12), for 3 months. In both studies, measurements of insulin sensitivity (euglycemic-hyperinsulinemic clamp) and plasma inflammatory and thrombotic factor concentrations were obtained on enrollment (studies 1 and 2) and after intervention (study 2). RESULTS: Study 1 demonstrated significant correlations between insulin sensitivity and plasma adiponectin, high-density lipoprotein cholesterol, plasminogen activator inhibitor 1, interleukin 6, tumor necrosis factor α, and triglycerides. Insulin sensitizer therapy significantly improved insulin sensitivity, inflammatory cytokines except interleukin 6, and thrombotic factors except fibrinogen, without concomitant changes in weight, blood pressure, or body composition. CONCLUSION:Insulin sensitizer therapy ameliorates inflammatory and thrombotic factors implicated in developing CVD. Interventions to improve insulin sensitivity may thus be considered as therapeutic options to reduce CVD burden in insulin-resistant states, although further research is needed to determine long-term effects on morbidity and mortality.
RCT Entities:
OBJECTIVE: To determine whether targeted pharmacological improvement of insulin sensitivity will normalize the associated elevations of thrombotic and inflammatory cardiovascular disease (CVD) biomarkers in individuals with insulin resistance. PATIENTS AND METHODS: Study 1 was a cross-sectional study of Asian Indians with and without diabetes mellitus and Northern European Americans without diabetes (n=14 each) conducted between December 11, 2003, and July 14, 2006. Study 2 was a secondary analysis of a double-blind randomized controlled study conducted between August 19, 2005, and August 24, 2010, that included 25 individuals with untreated diabetes or impaired fasting glucose who were randomized to receive placebo (n=13) or a combination of metformin, 1000 mg twice daily, and pioglitazone, 45 mg daily (n=12), for 3 months. In both studies, measurements of insulin sensitivity (euglycemic-hyperinsulinemic clamp) and plasma inflammatory and thrombotic factor concentrations were obtained on enrollment (studies 1 and 2) and after intervention (study 2). RESULTS: Study 1 demonstrated significant correlations between insulin sensitivity and plasma adiponectin, high-density lipoprotein cholesterol, plasminogen activator inhibitor 1, interleukin 6, tumor necrosis factor α, and triglycerides. Insulin sensitizer therapy significantly improved insulin sensitivity, inflammatory cytokines except interleukin 6, and thrombotic factors except fibrinogen, without concomitant changes in weight, blood pressure, or body composition. CONCLUSION:Insulin sensitizer therapy ameliorates inflammatory and thrombotic factors implicated in developing CVD. Interventions to improve insulin sensitivity may thus be considered as therapeutic options to reduce CVD burden in insulin-resistant states, although further research is needed to determine long-term effects on morbidity and mortality.
Authors: J B Meigs; M A Mittleman; D M Nathan; G H Tofler; D E Singer; P M Murphy-Sheehy; I Lipinska; R B D'Agostino; P W Wilson Journal: JAMA Date: 2000-01-12 Impact factor: 56.272
Authors: Burton E Sobel; Regina M Hardison; Saul Genuth; Maria M Brooks; Robert D McBane; David J Schneider; Richard E Pratley; Kurt Huber; Robert Wolk; Ashok Krishnaswami; Robert L Frye Journal: Circulation Date: 2011-07-18 Impact factor: 29.690
Authors: Salvatore Mottillo; Kristian B Filion; Jacques Genest; Lawrence Joseph; Louise Pilote; Paul Poirier; Stéphane Rinfret; Ernesto L Schiffrin; Mark J Eisenberg Journal: J Am Coll Cardiol Date: 2010-09-28 Impact factor: 24.094
Authors: William C Cushman; Gregory W Evans; Robert P Byington; David C Goff; Richard H Grimm; Jeffrey A Cutler; Denise G Simons-Morton; Jan N Basile; Marshall A Corson; Jeffrey L Probstfield; Lois Katz; Kevin A Peterson; William T Friedewald; John B Buse; J Thomas Bigger; Hertzel C Gerstein; Faramarz Ismail-Beigi Journal: N Engl J Med Date: 2010-03-14 Impact factor: 91.245
Authors: Ioanna Tzoulaki; Mariam Molokhia; Vasa Curcin; Mark P Little; Christopher J Millett; Anthea Ng; Robert I Hughes; Kamlesh Khunti; Martin R Wilkins; Azeem Majeed; Paul Elliott Journal: BMJ Date: 2009-12-03
Authors: Sara E Espinoza; Nicolas Musi; Chen-Pin Wang; Joel Michalek; Beverly Orsak; Terry Romo; Becky Powers; Alice Conde; Melody Moris; Darcy Bair-Kelps; Yan Li; Vinutha Ganapathy; Tyson E Jergensen; Lauri C Kelly; Rozmin Jiwani Journal: J Gerontol A Biol Sci Med Sci Date: 2020-01-01 Impact factor: 6.053
Authors: Brian A Irving; Rickey E Carter; Mattias Soop; Audrey Weymiller; Husnain Syed; Helen Karakelides; Sumit Bhagra; Kevin R Short; Laura Tatpati; Rocco Barazzoni; K Sreekumaran Nair Journal: Metabolism Date: 2015-01-22 Impact factor: 8.694
Authors: Michelle J Ormseth; Annette M Oeser; Andrew Cunningham; Aihua Bian; Ayumi Shintani; Joseph Solus; S Tanner; C Michael Stein Journal: Arthritis Res Ther Date: 2013 Impact factor: 5.156
Authors: Xiaohui Bian; Tomás P Griffin; Xiangyang Zhu; Md Nahidul Islam; Sabena M Conley; Alfonso Eirin; Hui Tang; Paula M O'Shea; Allyson K Palmer; Rozalina G McCoy; Sandra M Herrmann; Ramila A Mehta; John R Woollard; Andrew D Rule; James L Kirkland; Tamar Tchkonia; Stephen C Textor; Matthew D Griffin; Lilach O Lerman; LaTonya J Hickson Journal: BMJ Open Diabetes Res Care Date: 2019-12-15